BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2423652)

  • 41. Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute.
    Petera J; Macharová H; Pohanková R; Malír A; Coupek P; Konecný M; Patera J; Pecina J; Drbal J; Koukalová H; Vásová I
    Neoplasma; 2000; 47(2):129-32. PubMed ID: 10985481
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy.
    Straus DJ; Gaynor JJ; Myers J; Merke DP; Caravelli J; Chapman D; Yahalom J; Clarkson BD
    J Clin Oncol; 1990 Jul; 8(7):1173-86. PubMed ID: 1694235
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.
    Viviani S; Bonadonna G; Santoro A; Bonfante V; Zanini M; Devizzi L; Soncini F; Valagussa P
    J Clin Oncol; 1996 May; 14(5):1421-30. PubMed ID: 8622055
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
    Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
    J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
    Aleman BM; Raemaekers JM; Tomiŝiĉ R; Baaijens MH; Bortolus R; Lybeert ML; van der Maazen RW; Girinsky T; Demeestere G; Lugtenburg P; Lievens Y; de Jong D; Pinna A; Henry-Amar M;
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):19-30. PubMed ID: 17097834
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
    Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
    Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M;
    N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024
    [TBL] [Abstract][Full Text] [Related]  

  • 48. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial.
    Hancock BW; Vaughan Hudson G; Vaughan Hudson B; Bennett MH; MacLennan KA; Haybittle JL; Anderson L; Linch DC
    J Clin Oncol; 1992 Aug; 10(8):1252-8. PubMed ID: 1634914
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease.
    Tannir N; Hagemeister F; Velasquez W; Cabanillas F
    J Clin Oncol; 1983 Jul; 1(7):432-9. PubMed ID: 6199478
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term follow-up of advanced Hodgkin's disease patients treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin and bleomycin (SCAB).
    Wiernik PH; Schiffer CA
    J Cancer Res Clin Oncol; 1988; 114(1):105-7. PubMed ID: 2450876
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Treatment of Hodgkin's disease with alternately used drug combinations CVPP/ABVD].
    Gabryś K; Sciborski R; Kotlarek-Haus S
    Przegl Lek; 1988; 45(10):717-20. PubMed ID: 2469104
    [No Abstract]   [Full Text] [Related]  

  • 52. Hodgkin's disease in children: correlation of clinical characteristics, staging procedures, and treatment at the University of Minnesota.
    McClain KL; Heise R; Day DL; Lee CK; Woods WG; Aeppli D
    Am J Pediatr Hematol Oncol; 1990; 12(2):147-54. PubMed ID: 1696073
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
    Canellos GP; Anderson JR; Propert KJ; Nissen N; Cooper MR; Henderson ES; Green MR; Gottlieb A; Peterson BA
    N Engl J Med; 1992 Nov; 327(21):1478-84. PubMed ID: 1383821
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
    De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F
    Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.
    Carella AM; Congiu AM; Gaozza E; Mazza P; Ricci P; Visani G; Meloni G; Cimino G; Mangoni L; Coser P
    J Clin Oncol; 1988 Sep; 6(9):1411-6. PubMed ID: 2458439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease.
    Klimo P; Connors JM
    J Clin Oncol; 1985 Sep; 3(9):1174-82. PubMed ID: 2411881
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy.
    Santoro A; Bonadonna G; Valagussa P; Zucali R; Viviani S; Villani F; Pagnoni AM; Bonfante V; Musumeci R; Crippa F
    J Clin Oncol; 1987 Jan; 5(1):27-37. PubMed ID: 2433409
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
    Mjaaland I; Ganser D; Freitag EM; Bohndorf W
    Strahlenther Onkol; 1994 Sep; 170(9):516-23. PubMed ID: 7524173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.